25 July 2019  
EMA/CHMP/416776/2019  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Lonsurf 
trifluridine / tipiracil 
On 25 July 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Lonsurf. The 
marketing authorisation holder for this medicinal product is Les Laboratoires Servier. 
The CHMP adopted a new indication for gastric cancer and a change to the existing indication for colorectal 
cancer. The full indications for Lonsurf will now be as follows 2: 
“Colorectal cancer 
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal 
cancer (CRC) who have been previously treated with, or are not considered candidates for, 
available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, 
anti-VEGF agents, and anti EGFR agents. 
Gastric cancer 
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic 
gastric cancer including adenocarcinoma of the gastroesophageal junction, who have 
been previously treated with at least two prior systemic treatment regimens for 
advanced disease (see section 5.1)”. 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
                                                
